Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: A comparison of mathematical models

AIDS

Volumn 27, Issue 18, 2013, Pages 2943-2951

  Vijver, David A M C Van De ^a   Nichols, Brooke E ^a   Abbas, Ume L ^b   Boucher, Charles A B ^a   Cambiano, Valentina ^c   Eaton, Jeffrey W ^d   Glaubius, Robert ^b   Lythgoe, Katrina ^d   Mellors, John ^e   Phillips, Andrew ^c   Sigaloff, Kim C ^f   Hallett, Timothy B ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; HIV 1; Preexposure prophylaxis; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE;

AFRICA SOUTH OF THE SAHARA; ARTICLE; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MACHA TRANSMISSION MODEL; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SOUTH AFRICAN TRANSMISSION MODEL; SYNTHESIS TRANSMISSION MODEL; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; THEORETICAL MODEL; UTILIZATION; VIROLOGY; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; ORGANOPHOSPHONATES; PRE-EXPOSURE PROPHYLAXIS; YOUNG ADULT;

EID: 84888306740     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000433237.63560.20     Document Type: Article

References (37)

1. UNAIDS. Global report. UNAIDS report on the global AIDS epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
6. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections. 2013, Atlanta: March 3-6. Abstract no. 26LB.
7. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of preexposure prophylaxis. Curr Opin Infect Dis 2010; 23:621-627.
8. Hurt CB, Eron JJ Jr, Cohen MS. Preexposure prophylaxis and antiretroviral resistance: HIV prevention at a cost Clin Infect Dis 2011; 53:1265-1270.
9. WHO. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organisation; 2009, http://www.who.int/hiv/ pub/arv/rapid-advice-art.pdf. pp. 1-28.
10. FDA. Press announcement: FDA approves first drug for reducing the risk of sexually acquired HIV infection. Evidence-based approach enhances existing prevention strategies. Silver Spring, MD: US Food and Drug Administration; 2012.
11. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007; 2:e875.
12. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral preexposure prophylaxis (PrEP). PLoS One 2011; 6:e18165.
13. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and preexposure prophylaxis: combined impact on HIV-1 transmission and drug resistance in South Africa. J Infect Dis 2013; 208:224-234.
14. Nichols BE, Boucher CA, van Dijk JH, Thuma PE, Nouwen JL, Baltussen R, et al. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: A modeling study. PLoS One 2013; 8:e59549.
15. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-850.
16. Cambiano V, Pillay D, Lundgren J, Phillips A. Preexposure prophylaxis: Impact on resistance of targeting sero-discordant couples. Journal of the International AIDS Society. 19th International AIDS Conference, Washington, DC, July 22-27 2012. Abstract no. LBPE26.
17. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after firstline antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: Implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-1669.
18. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
19. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
20. UK-CHIC. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50:1275-1285.
21. Nichols BE, Boucher CA, van de Vijver DA. HIV testing and antiretroviral treatment strategies for prevention of HIV infection: Impact on antiretroviral drug resistance. J Intern Med 2011; 270:532-549.
22. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. Lancet Infect Dis 2010; 10:155-166.
23. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: A systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
24. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
25. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006; 11:329-334.
26. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1627-1631.
27. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-28.
28. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-1419.
29. van de Vijver DA, Derdelinckx I, Boucher CA. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009; 199:1310-1317.
30. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
31. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203:1174-1181.
32. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011; 305: 1327-1335.
33. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
34. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of preexposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646.
35. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of preexposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One 2008; 3:e2077.
36. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730.
37. Michael NL. Oral preexposure prophylaxis for HIV-another arrow in the quiver N Engl J Med 2010; 363:2663-2665.